Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Despite recent significant advances in genomic techniques, there are currently no practice guidelines for the clinical implementation of genomics.

The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), in association with researchers at the University of Oxford and the Harvard Stem Cell Institute have today published an Opinion piece in Nature Medicine, which recommends the development of ‘Good Genomic Practice’ (GGP) guidelines. Like good laboratory practice (GLP) and good manufacturing practice (GMP), GGP aims to ‘ensure the quality and consistency of medical research and practice’ in the field.

The proposed guidelines would address the ethical, scientific, quality assurance, data handling and storage issues surrounding genomic diagnosis, setting out best practice principles from ‘initial sample collection to the ultimate clinical decision.

Good practice guidelines in this field would result in greater consistency in the reported results as well as an improved understanding of the clinical significance of genetic variants. Not only is this a step towards stratifying medicine; but also the development of integrated global databases with standardized formats, bringing the ultimate goal of truly personalizing treatments closer.

The authors suggest that international leaders in the genomics field should create a checklist to map out the key stages in the process that require standardization and then work with wider stakeholders to formulate guidelines.  Defining the parameters of GGP at this early stage will ensure that the field realizes its ‘boundless potential to improve human health.’


Links:

Original paper in Nature

CASMI

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

Clinical Trials Coronavirus COVID-19 General Research

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19.

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).